cisplatin + doxorubicin + edatrexate + filgrastim + vinblastine

This is a combination chemotherapy regimen consisting of cisplatin (a platinum-based alkylating agent), doxorubicin (an anthracycline), edatrexate (an antifolate similar to methotrexate), vinblastine (a vinca alkaloid), and filgrastim (a granulocyte colony-stimulating factor). The chemotherapeutic agents in this combination work through different mechanisms to inhibit cancer cell growth and division, while filgrastim is likely included to manage neutropenia, a common side effect of chemotherapy. This combination appears to be a modification of the M-VAC regimen (which uses methotrexate instead of edatrexate and doesn't include filgrastim) that has been used for treating urothelial carcinomas.